



NIH AIDS Reagent Program
20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent:	CEF Control Peptide Pool
Catalog Number:	9808
Lot Number:	65415
Provided:	0.5 mg net each peptide
Sequence:	See attached table. MHC class I restricted T cell epitopes from human cytomegalovirus, Epstein Barr virus and influenza virus.
Analytical Test:	HPLC, mass spectrometry, amino acid sequencing and N-terminal sequencing were used to determine the sequence and purity. See attached table for estimated purity.
Solubility:	This peptide pool is soluble in DMSO. Once a peptide is in solution, the DMSO can be slowly diluted with aqueous medium. Care must be taken to ensure that the peptide does not begin to precipitate out of solution. Please note: Recent unpublished reports indicate that Cys and Met containing peptide sequences are highly unstable when stored in DMSO for prolonged periods of time. Degradation of these peptides in DMSO can occur within days to weeks. Although a correlation between peptide decay and effect on biological activity is currently unknown, for prolonged peptide stability, we recommend freshly prepared working solutions from freeze dried aliquots of these and other peptide pools.
Special Characteristics:	The pool of 32 cytomegalovirus, Epstein Barr virus and influenza virus (CEF) peptides stimulates CD8+ T cells to produce IFNγELISPOT, intracellular cytokine, and CTL assays were used to determine activity. The CEF pool is useful for QC of ELISPOT, CTL and intracellular cytokine assays. The CEF pool stimulates release of IFNγ from CD8+ T cells in individuals with defined HLA types. See attached Table. Click here to see the table for this peptide pool.
Recommended Storage:	-20°C

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Contributor: DAIDS, NIAID.

References: Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, Ferrari G, Birx DL, Cox JH. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. *J Immunol Methods* **260**:157-172, 2002.

Mwau M, McMichael A and Hanke T. Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. *AIDS Res Hum Retroviruses* **18**: 611-8, 2002.

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: CEF Control Peptide Pool from DAIDS, NIAID."

Last Updated: April 07, 2014

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.